CN116348488A - 犬白介素-31受体α的犬源化大鼠抗体 - Google Patents

犬白介素-31受体α的犬源化大鼠抗体 Download PDF

Info

Publication number
CN116348488A
CN116348488A CN202180070828.2A CN202180070828A CN116348488A CN 116348488 A CN116348488 A CN 116348488A CN 202180070828 A CN202180070828 A CN 202180070828A CN 116348488 A CN116348488 A CN 116348488A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
canine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180070828.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·莫尔塞耶
张远征
A·萨哈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CN116348488A publication Critical patent/CN116348488A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180070828.2A 2020-10-15 2021-10-14 犬白介素-31受体α的犬源化大鼠抗体 Pending CN116348488A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063092296P 2020-10-15 2020-10-15
US202063092294P 2020-10-15 2020-10-15
US63/092,296 2020-10-15
US63/092,294 2020-10-15
US202063127184P 2020-12-18 2020-12-18
US63/127,184 2020-12-18
US202163235258P 2021-08-20 2021-08-20
US202163235257P 2021-08-20 2021-08-20
US63/235,258 2021-08-20
US63/235,257 2021-08-20
PCT/EP2021/078385 WO2022079138A1 (en) 2020-10-15 2021-10-14 Caninized rat antibodies to canine interleukin-31 receptor alpha

Publications (1)

Publication Number Publication Date
CN116348488A true CN116348488A (zh) 2023-06-27

Family

ID=78302732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180070828.2A Pending CN116348488A (zh) 2020-10-15 2021-10-14 犬白介素-31受体α的犬源化大鼠抗体

Country Status (8)

Country Link
US (2) US12577310B2 (enExample)
EP (2) EP4229083A1 (enExample)
JP (2) JP7905331B2 (enExample)
CN (1) CN116348488A (enExample)
AU (2) AU2021359068A1 (enExample)
CA (2) CA3194384A1 (enExample)
MX (2) MX2023004439A (enExample)
WO (2) WO2022079139A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118063607A (zh) * 2024-03-16 2024-05-24 珠海市丽珠单抗生物技术有限公司 抗犬il-31抗体及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
JP7905331B2 (ja) * 2020-10-15 2026-08-14 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
CN118359715B (zh) * 2023-11-27 2025-08-19 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
WO2010031184A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3954710A3 (en) 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US11091556B2 (en) * 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
CN110563844A (zh) 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
JP7905331B2 (ja) 2020-10-15 2026-08-14 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118063607A (zh) * 2024-03-16 2024-05-24 珠海市丽珠单抗生物技术有限公司 抗犬il-31抗体及其用途

Also Published As

Publication number Publication date
JP7905331B2 (ja) 2026-08-14
US12703751B2 (en) 2026-08-11
JP2023545183A (ja) 2023-10-26
AU2021360208A9 (en) 2025-03-27
WO2022079138A1 (en) 2022-04-21
EP4229083A1 (en) 2023-08-23
JP7902808B2 (ja) 2026-08-10
US20240002518A1 (en) 2024-01-04
WO2022079139A1 (en) 2022-04-21
US20230391879A1 (en) 2023-12-07
AU2021359068A9 (en) 2024-06-06
AU2021359068A1 (en) 2023-06-15
MX2023004438A (es) 2023-05-08
US12577310B2 (en) 2026-03-17
AU2021359068A8 (en) 2023-06-22
JP2023545182A (ja) 2023-10-26
CA3194384A1 (en) 2022-04-21
CA3194457A1 (en) 2022-04-21
AU2021360208A1 (en) 2023-04-27
EP4229084A1 (en) 2023-08-23
MX2023004439A (es) 2023-05-08

Similar Documents

Publication Publication Date Title
JP7719077B2 (ja) アトピー性皮膚炎を処置するための二重特異性イヌ化抗体および二重特異性結合パートナー
US12577310B2 (en) Caninized antibodies to canine interleukin-31 receptor alpha
CN107683291B (zh) 针对犬白介素-4受体α的抗体
CN114867526B (zh) 犬白介素-4受体α的抗体
WO2023111128A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha ii
CN116472287A (zh) 犬白介素-31受体α的犬源化抗体
RU2855920C1 (ru) Канинизированные антитела против альфа-рецептора интерлейкина-31 собаки
RU2854833C1 (ru) Биспецифические канинизированные антитела и биспецифические партнеры по связыванию для лечения атопического дерматита
RU2854627C1 (ru) Биспецифические канинизированные антитела для лечения атопического дерматита
CN118891282A (zh) 犬白介素-31受体αII的犬源化抗体
HK40113191A (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
CN118401549A (zh) 人ngf的犬源化和猫源化抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination